QTc Prolongation Associated With Psychotropics: Therapeutic Considerations
A focus on QTc monitoring in patients receiving psychotropics, especially when multiple medications are prescribed.
Table – Risk factors for QTc prolongation
Figure. Observed cardiac action potential from ECG
Evaluating a Patient With QTc Interval Prolongation Risk
Premiere Date: March 20, 2016
Expiration Date: September 20, 2017
This activity offers CE credits for:
1. Physicians (CME)
2. Other
ACTIVITY GOAL
This article focuses on the importance of QTc monitoring in patients receiving psychotropics, especially when multiple medications are prescribed.
LEARNING OBJECTIVES
At the end of this CE activity, participants should be able to:
• Explain the need for QTc monitoring
• Identify the medications that are most likely to increase the risk of QT prolongation
• Define the patient characteristics that increase the risk of QT prolongation
• Describe the lifestyle factors that exacerbate the risk of QT prolongation and cardiovascular effects
TARGET AUDIENCE
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CREDIT INFORMATION
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for 1.5 AMA PRA Category 1 Credit™.
DISCLOSURE DECLARATION
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Megan B. McCorkle, BA, has no disclosures to report.
Nicole B. Washington, DO, has no disclosures to report.
Nancy C. Brahm, PharmD, MS, BCPP, CGP, has no disclosures to report.
Julie Kissack, PharmD, BCPP, FCCP, has no disclosures to report.
Gollapudi Shankar, MS, PharmD, BCPP, CGP, PhC, (peer/content reviewer) has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
Psychotropic medications, such as antipsychotics and antidepressants, prolong ventricular repolarization in varying severity. Patients with psychiatric disorders frequently have coexisting medical conditions and substance use disorders and may require multiple medications. In addition, they may exhibit multiple independent risk factors for cardiac disturbances.1
QT prolongation during medication exposure is of particular importance because it is a marker for disruption in cardiac conduction. The QT interval represents the amount of time for ventricular depolarization and repolarization and is measured from the start of the QRS wave complex to the end of the T wave. The QT interval varies secondary to heart rate. For this reason, the corrected QT interval (QTc) is used for heart rates that exceed 60 beats per minute. The QT interval time is approximately equal for men and women (< 420 msec vs < 430 msec).2,3
CASE VIGNETTE
MF is a 52-year-old white woman who has bipolar I disorder with mania. She receives community-based integrated multidisciplinary services for medication management and adherence as well as social and psychiatric support. MF smokes a pack of cigarettes daily and has a history of alcohol abuse. She has no history of medication allergies or cardiac conduction abnormalities.
During a recent inpatient psychiatric admission, a baseline electrocardiogram (ECG) showed a QTc interval of 507 msec. MF’s medication regimen includes haloperidol decanoate 200 mg intramuscular injection every 3 weeks, divalproex sodium extended-release 500 mg tablet once daily, fluvoxamine 50 mg tablet once daily, hydroxyzine 50 mg tablet once daily, tramadol 50 mg tablet 4 times daily, and zolpidem 10 mg once nightly at bedtime.
MF represents a typical patient seen in the psychiatric inpatient setting. She exhibits multiple independent risk factors for QTc prolongation: female gender, history of alcohol dependence, and current tobacco use. Individually, the medications prescribed for MF are not significant for lengthening the QT interval1,2; however, the combination of these psychotropic medications predisposes MF to life-threatening cardiac disturbances. Her baseline QT interval of 507 msec represents a risk factor for arrhythmia. Although all medications were continued to achieve psychiatric stabilization, increased cardiac monitoring was used during the hospitalization because of MF’s baseline QT interval.
QTc/JT interval
The JT interval is more representative of cellular conditions of the heart that result in repolarization.4 Medications that prolong QTc also increase cardiac repolarization, which may heighten the risk of re-entrant arrhythmias, such as torsades de pointes (TdP), and which could be observed on the JT interval. Current data do not report the JT intervals; however, future studies that include this value would help inform practitioners about the risk of TdP.4,5
The QT interval remains a reliable measure for cardiac action potentials and is easily assessed by ECG. QTc is useful to clinicians because variability in action potential duration is a key predictor of cardiac disturbances; a faster heart rate is associated with shorter QT intervals.1,2 QTc prolongation above 500 msec is a risk factor for TdP (polymorphic ventricular tachycardia), a life-threatening ventricular arrhythmia that requires immediate intervention. (The Figure shows the cardiac action potential.)
Pharmacological variables
The mechanism of action of psychotropic medications primarily leads to lengthening of the QT interval via inhibition of potassium channels.1 In combination, psychotropic medications can predispose patients to arrhythmias due to excessive potassium channel inhibition that affects repolarization.
The hERG gene is accountable for the expression of potassium channels involved in myocyte repolarization. Genomic studies have identified genome variants that predispose patients to medication-induced QTc prolongation.6 These rare mutations increase a patient’s risk of TdP secondary to medication therapy.3 Studies have shown that patient-specific genetic factors alter drug metabolism.6,7 Consequently, genetic screening may provide information that will help with successful medication selection. Because of the extensive interplay between patient-specific considerations and medication-specific properties, careful selection of psychotropic medication should be determined on a case-by-case basis.
Medications known to produce QTc prolongation include antidepressants and antipsychotics. Prescribers should evaluate the appropriateness of treatment and the need for additional cardiovascular monitoring when these medications are used. Patient-specific factors should be assessed in each case. Independent risk factors for the development of QTc prolongation include, but are not limited to, age older than 65 years, female gender, existing cardiac condition or abnormality, electrolyte disturbances, concurrent psychiatric disorders, and excessive plasma concentrations of the medication in question. Comorbidities, such as substance use (including alcohol) disorders, have synergistic, rather than additive, effects on QT interval lengthening, which probably results from increased cardiotoxic activity. The Table provides a complete list of risk factors for QTc prolongation.
Antidepressants
TCAs
TCAs cause QTc prolongation via QRS widening. TCAs block sodium, chloride, and potassium channels. Amitriptyline, doxepin, imipramine, desipramine, and nortriptyline all prolong the QT interval. Maprotiline is associated with the highest QTc prolongation, lengthening the QTc interval by 17 msec.8 Clomipramine exhibits the least QTc prolongation.1 All of these agents have been implicated in TdP. TCAs should not be used in patients with cardiovascular complications or abnormalities because of the potential for adverse cardiac events.
SSRIs
SSRIs are more frequently used than TCAs. SSRIs have been implicated in dose-dependent QTc prolongation when administered at supratherapeutic doses.2,9,10
Citalopram is the most controversial because of its degradation into the active metabolite, didesmethylcitalopram, which appears to have a toxic effect on cytochrome P-450 (CYP450) 2D6 ultrarapid metabolizers.1,2,9 Current FDA recommendations limit citalopram to a total daily dose of 40 mg, although these dosing parameters may err on the conservative side. The data conflict regarding whether citalopram alone is the causative factor of QTc prolongation.9
The mechanism of action of psychotropic medications primarily leads to lengthening of the QT interval via inhibition of potassium channels.
The FDA dosing restriction of citalopram has not been extended to escitalopram. Escitalopram and sertraline lengthen the QT interval by 7 msec and 3 msec, respectively.1,9 Fluoxetine poses a higher risk in the presence of independent risk factors; however, QTc prolongation has not been observed with fluoxetine.2,8,9 Paroxetine has not been implicated in QTc prolongation.9 Interestingly, fluvoxamine demonstrated QTc shortening at a measured -5 msec.2
Other agents
Vilazodone is a serotonin agonist/antagonist. It has not been implicated in ECG abnormalities; however, strong CYP P450 inhibitors can increase serum concentrations to supratherapeutic levels.11 Desvenlafaxine has not been found to cause significant QT prolongation.12 Because of limited data, further studies are required to confirm the safety and efficacy of these agents when combined with other psychotropic medications.
Duloxetine and venlafaxine are serotonin and norepinephrine reuptake inhibitors. Duloxetine has not been implicated in QTc prolongation.1 Venlafaxine should be avoided in patients with cardiovascular disease because of potential cardiotoxicity. Newer agents such as levomilnacipran and milnacipran have not exhibited significant effects on cardiac repolarization.13,14 However, data are limited on these agents, and further research is required.
Bupropion, a norepinephrine reuptake inhibitor, has not been implicated in QTc prolongation. Mirtazapine increased QTc prolongation by roughly 3 msec, although it is significantly higher in cases of overdose. Trazodone has shown mild QTc prolongation, most notable in cases of overdose.1
Antipsychotics
Typical antipsychotics
Phenothiazines have the potential to be arrhythmogenic and are more likely to result in TdP than other psychotropic medications; the highest risk of producing QT prolongation was seen with thioridazine.1,8 Caution should be exercised when prescribing these medications to patients with existing risk factors. Low-potency antipsychotics, such as chlorpromazine, lengthen the QT interval in a dose-dependent manner (chlorpromazine caused TdP only at high doses1). Additional monitoring of the QT interval is recommended with thioridazine or chlorpromazine.
Haloperidol, a high-potency antipsychotic, increases the risk of QTc prolongation-the intravenous formulation poses the highest risk.1,2 Geriatric patients are at increased risk for QTc prolongation with any formulation; thus, additional monitoring of QT interval lengthening in this population is warranted.
Other high-potency antipsychotics and agents with related structures, such as pimozide and fluphenazine, have been implicated in significant QTc prolongation.1 Droperidol, a butyrophenone, has also been seen to prolong the QTc interval.15 Droperidol is of highest concern when used in combination with other known QTc-prolonging medications. Pimozide and droperidol can cause TdP.1,15
Atypical antipsychotics
As a class, atypical antipsychotics are associated with less QTc prolongation potential; however, there is no indication that they pose less risk of TdP. Ziprasidone causes significant QTc prolongation. Long-term use of this agent is associated with the most significant QTc prolongation: 20 msec.8 Ziprasidone extends the duration of repolarization in a dose-independent manner.1
Minor QTc prolongation has been reported with olanzapine and risperidone, when either is used as a single agent or at low daily doses (ie, < 20 mg olanzapine; < 4 mg risperidone).1,8 The QTc prolongation potential of lurasidone is similar to that of olanzapine. However, the trials were small, and further research is needed. Available data suggest that lurasidone has better patient adherence because of once-daily dosing.16
Quetiapine exhibited QTc prolongation and resultant TdP.2 Asenapine monotherapy did not exhibit QTc prolongation above 500 msec but did exhibit QT prolongation comparable to that of quetiapine.6 Olanzapine, risperidone, and quetiapine showed less QTc prolongation potential than did thioridazine.1
Iloperidone and paliperidone have exhibited the highest risk of QT interval lengthening in observed data.1 QTc prolongation of roughly 9 msec in therapeutic trials of iloperidone has been reported; however, in the presence of concurrent paroxetine treatment, these values extended to 15.4 msec.17 Strong CYP2D6 and 3A4 inhibitors, such as paroxetine and ketoconazole, added to iloperidone or paliperidone therapy will significantly raise antipsychotic blood levels and may result in an increased QT interval.
Clozapine is frequently reserved for treatment resistance because of the potential for adverse cardiac effects of myocarditis and cardiomyopathy. Clozapine is typically reserved for last-line therapy because it prolongs the QT interval in a dose-dependent manner and is associated with an increased incidence of TdP.8
Lifestyle variables
Substance use disorders
Concurrent use of cocaine and alcohol results in cocaethylene, which has a synergistic cardiotoxic potential compared with individual alcohol or cocaine exposure.18 Clinicians should recognize these risk factors when they prescribe medications that can exacerbate existing cardiovascular risk.
Chronic ingestion of alcohol has been observed to result in cardiac insult. The destruction of the autonomic nervous system is due to acetaldehyde, which is the toxic substance that causes QT interval lengthening.19 QTc lengthening predisposes alcohol-dependent patients to cardiac arrhythmia independent of electrolyte disturbance. Furthermore, a pharmacodynamic interaction occurs with acute alcohol ingestion that inhibits the metabolism of TCAs. When TCAs are not cleared, increased serum concentrations can potentially result in medication overdose.7,19
Decreased liver function poses additional risk for adverse events due to decreased metabolic activity.8 Consider the influence of alcohol, in combination with psychotropic agents, on QTc prolongation.
Tobacco use
Tobacco use, particularly smoking, is common among psychiatric patients. It is important to encourage patients and inform them of resources available for tobacco cessation. Components of tobacco smoke enhance cardiovascular risk as an independent risk factor for QTc prolongation. Nicotine has the potential to alter CYPP450 metabolism and further lengthen QT intervals (although these data are not conclusive in human models).20
Conclusion
Patients who receive psychotropic treatment are at increased risk for QTc prolongation, and multiple medications further increase risk. The synergistic effect of QT-prolonging agents in combination with patient-specific factors highlights the importance of discretion in therapeutic management. Identifying potential risk factors will aid providers in selecting the most appropriate drug therapy.
POST-TEST
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/PT (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This Web site supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit http://www.neurosciencecme.com/technical.asp.
PLEASE NOTE THAT THE POST-TEST IS AVAILABLE ONLINE ONLY ON THE 20TH OF THE MONTH OF ACTIVITY ISSUE AND FOR A YEAR AFTER.
Disclosures:
Ms McCorkle is Student Pharmacist, Class of 2017, Harding University College of Pharmacy, Searcy, AR; Dr Washington is Staff Psychiatrist, Family and Children’s Services, Inc, Crisis Care Center, Tulsa, OK; Dr Brahm is Clinical Professor, University of Oklahoma College of Pharmacy, Tulsa, OK; and Dr Kissack is Professor and Chair, Pharmacy Practice, Harding University College of Pharmacy, Searcy, AR.
References:
1. Beach SR, Celano CM, Noseworthy PA, et al. Review article: QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54:1-13.
2. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Aerztebl Int. 2011;108:687-693.
3. Miura N, Saito T, Taira T, et al. Risk factors for QT prolongation associated with acute psychotropic drug overdose. Am J Emerg Med. 2015;33:142-149.
4. Hacihamdioglu D, Fidanci K, Kilic A, et al. QT and JT dispersion and cardiac performance in children with neonatal Bartter syndrome: a pilot study. Pediatr Nephrol. 2013;28:1969-1974.
5. Wu C-S, Tsai Y-T, Tsai H-J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015;4:pii e001568.
6. Ã berg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12:165-172.
7. Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4:1-6.
8. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5:97-104.
9. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psych. 2014;75:e441-e449.
10. Johnsen E, Aanesen K, Sriskandarajah S, et al. QTc prolongation in patients acutely admitted to hospital for psychosis and treated with second generation antipsychotics. Schizophr Res Treat. Dec 31, 2013; Epub ahead of print.
11. Sproule B, Hazra M, Pollock B. Desvenlafaxine succinate for major depressive disorder. Drugs Today. 2008;44:475-487.
12. Gazewood JD, Slayton P, Degeorge K. Vilazodone (Viibryd) for the treatment of depression. Am Fam Phys. 2013;88:263-264.
13. Mago R, Forero G, Greenberg WM, et al. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Invest. 2013;33:761-771.
14. Periclou A, Palmer RH, Hongjie Zheng, Lindamood III C. Effects of milnacipran on cardiac repolarization in healthy participants. J Clin Pharmacol. 2010;50:422-433.
15. Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. Br J Clin Pharmacol. 2014;77:880-886.
16. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat. 2012;8:155-168.
17. Lam LW. Comparison of QT prolongation among iloperidone, quetiapine, and ziprasidone. Brown Univ Psychopharm Update. 2013;24:2-3.
18. Brache K, Stockwell T, Macdonald S. Functions and harms associated with simultaneous polysubstance use involving alcohol and cocaine. J Subst Use. 2012;17:399-416.
19. Corovic N, Durakovic Z, Misigoj-Durakovic M. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients. Clin Exp Res. 2006;30:150-154.
20. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011;25:503-510.
